ea0098c15 | Clinical – Chemo/SSA/Biologics | NANETS2023
Chauhan Aman
, Kolesar Jill
, Yan Donglin
, Hao Zhonglin
, McGarry Ronald
, Villano John
, Zinner Ralph
, Maskey Ashish
, Miller Jordan
, Mullett Timothy
, Khurana Aman
, Zhou Xitong
, Gupta Garima
, Flora Daniel
, Darnell Colleen
, O'Neil Richard
, Kunos Charles
, Anthony Lowell
, Arnold Susanne
Background: Immune checkpoint inhibitor (ICI) maintenance therapy is the standard of care for frontline management of extensive-stage small cell lung cancer (ES SCLC). However, the overall survival benefit of the addition of ICI maintenance to frontline ES SCLC treatment is modest and further improvement is needed. We hypothesized that the addition of poly (ADP-ribose) polymerase inhibition to ICI maintenance therapy for patients with platinum-sensitive ES SCLC could improve t...